<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Autoimmune CL-rA need a plasma protein, beta 2GPI, to bind anionic PL </plain></SENT>
<SENT sid="1" pm="."><plain>While beta 2GPI could be the true antigen, beta 2GPI binding to solid phase <z:chebi fb="5" ids="28304">heparin</z:chebi> did not determine its recognition by CL-rA when using patient plasmas </plain></SENT>
<SENT sid="2" pm="."><plain>We tested plasmas from four patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> in this study and no CL-rA binding to <z:chebi fb="5" ids="28304">heparin</z:chebi> <z:chebi fb="0" ids="2511">sepharose</z:chebi> was obtained </plain></SENT>
<SENT sid="3" pm="."><plain>On the contrary, when CL-rA were first purified from the plasmas by means of a CL-<z:chebi fb="0" ids="25657">octyl</z:chebi> <z:chebi fb="0" ids="2511">sepharose</z:chebi> column, the purified material bound to the <z:chebi fb="5" ids="28304">heparin</z:chebi> <z:chebi fb="0" ids="2511">sepharose</z:chebi> column </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, after recognizing beta 2 GPI, CL-rA bind <z:chebi fb="5" ids="28304">heparin</z:chebi>. 'In vivo' CL-rA binding to <z:chebi fb="5" ids="28304">heparin</z:chebi> like-substances could inhibit the anti-thrombotic properties of endothelial cells </plain></SENT>
</text></document>